α-Klotho protein

Global cell therapy manufacturing market projected to reach $14B by 2035, with FDA regulatory flexibility accelerating approvals and multiple biotech companies advancing scalable production capabilities.

Avaí Bio achieves critical Master Cell Bank milestone for α-Klotho protein therapy, partnering with Austrianova as cell therapy market surges toward $45B by 2035.

Avaí Bio begins manufacturing genetically modified cells overexpressing α-Klotho protein, an anti-aging compound that naturally declines 50% after age 40, advancing its Cell-in-a-Box platform.